In exchange for Japanese co-development and co-commercialisation rights to its rheumatoid arthritis biologic Orencia® (abatacept), Bristol-Myers Squibb (BMS) has gained expanded territorial rights from Ono Pharmaceutical to BMS-936558/ONO-4538, an anti-programmed cell death (PD-1) antibody in Phase I and II clinical trials in the US for a number of tumour types. BMS already had rights to develop and commercialise the cancer immunotherapy in North America as a result of its 2009 acquisition of Medarex and it now has rights in the rest of the world, except in Japan, Korea and Taiwan.